`D ate filed :O ctober4,2017
`
`Filed O n B ehalf O f:
`
`N ovartis A G
`
`B y:
`
`N icholas N .Kallas
`N Kallas@ fchs.com
`ZortressA finitorIP R@ fchs.com
`(212)218 -2100
`
`UN ITE D S TA TE S P A TE N T A N D TRA D E M A RK O FFIC E
`
`B EFO RE TH E P A TEN T TRIA L A N D A P P EA L B O A RD
`
`P A R P H A RM A C EUTIC A L ,IN C .,
`A RGEN TUM P H A RM A C EUTIC A L L L C ,A N D
`W EST-W A RD P H A RM A C EUTIC A L S
`IN TERN A TIO N A L L IM ITED
`P etitioners,
`
`v.
`
`N O V A RTIS A G,
`P atentO wner.
`
`C ase IP R2016-0147 91
`P atentN o.9,006,224
`
`P A TE N T O W N E R’S UP D A TE D M A N D A TO RY
`N O TIC E S UN D E R 37 C .F.R.§ 42.8 (a)(2)
`
`1 A rgentu m P harmaceu ticalL L C was joined as apartyto this proceed ingviaa
`M otion forJoind erin IP R2017 -01063;W est-W ard P harmaceu ticals International
`L imited was joined as apartyviaaM otion forJoind erin IP R2017 -0107 8 .
`
`
`
`P u rsu antto the requ irements of37 C .F.R.§ 42.8 (a)(3),N ovartis A G
`
`(“N ovartis”or“P atentO wner”)su bmits the followingu pd ate to its A u gu st12,
`
`2016 P atentO wner’s M and atoryN otices (P aper4).
`
`RE A L P A RTY -IN -IN TE RE S T P URS UA N T TO 37 C .F.R.§ 42.8 (b)(1)
`
`The realparty-in-interestinformation has notchanged .
`
`RE L A TE D M A TTE RS P URS UA N T TO 37 C .F.R.§ 42.8 (b)(2)
`
`Since P atentO wnersu bmitted its originalM and atoryN otices (P aper4),the
`
`’224 P atenthas been asserted in the followingpatentinfringementlawsu its:(1)
`
`N ovartis P harm.C orp.etal.v.TevaP harmaceu ticals USA ,Inc.,N os.17 -393-
`
`RA G,17 -8 67 -RGA (D .D el.).
`
`The ’224 P atentis also the su bjectof the followingP etitions forInter Partes
`
`Review:A rgentu m P harm.L L C v.N ovartis A G,Inter Partes Review N o.2017 -
`
`01063(P .T.A .B .)and W est-W ard P harms.Int’lL td .v.N ovartis A G,Inter Partes
`
`Review N o.2017 -0107 8 (P .T.A .B .),whichhave recentlybeen joined withthis
`
`Inter Partes Review (IP R2017 -01063,P aper11;IP R2017 -0107 8 ,P aper9).
`
`Since P atentO wnersu bmitted its M and atory N otices (P aper4),the
`
`followingotherpatentinfringementlawsu its involvingd ifferentpatents thatcover
`
`the same prod u ctas the proceed ings have been filed :
`
`1
`
`
`
`(1)N ovartis P harms.C orp.etal.v.B reckenrid ge P harm.,Inc.,N o.17 -420
`
`(D .D el.);(2)N ovartis P harms.C orp.etal.v.M ylan P harms.Inc.,N o.17 -38 9-
`
`RGA (D .D el.);(3)N ovartis P harms.C orp.etal.v.M ylan P harms.Inc.,N o.17 -
`
`54-IM K (D .W .V a.).
`
`Since P atentO wnersu bmitted its M and atory N otices (P aper4),the
`
`followingotherInter Partes Review proceed inginvolvingad ifferentpatentthat
`
`covers the same prod u ctas the proceed ings has been filed :
`
` U.S .P atentN o.8 ,410,131:B reckenrid ge P harm.,Inc.v.N ovartis
`
`P harms.C orp.,Inter Partes Review N o.2017 -01592 (P .T.A .B .).
`
`ID E N TIFIC A TIO N O FL E A D A N D B A C K-UP C O UN S E L
`P URS UA N T TO 37 C .F.R.§ § 42.8 (b)(3)and 42.10
`
`The lead cou nselinformation has notchanged .
`
`The P atentO wnerherebynotifies the B oard thatitis removingback-u p
`
`cou nselRaymond R.M and ra(Reg.N o.34,38 2)and ad d ingattorneyof record
`
`C harlotte Jacobsen (ad mitted pro hac vice)as back-u pcou nsel,as wellas P eterJ.
`
`W aibel(Reg.N o.43,228 )and GregoryD .Ferraro (Reg.N o.36,134)as ad d itional
`
`back-u pcou nsel,as shown below.A llothercou nselinformation remains the
`
`same.
`
`L ead C ou nsel
`N icholas N .Kallas
`FITZP A TRIC K,C EL L A ,H A RP ER &
`SC IN TO
`
`B ack-UpC ou nsel
`C harlotte Jacobsen (pro hac vice)
`FITZP A TRIC K,C EL L A ,H A RP ER &
`SC IN TO
`
`2
`
`
`
`1290 A venu e ofthe A mericas
`N ew Y ork,N Y 10104-38 00
`Tel.212-218 -2100
`nkallas@ fchs.com
`A dditionalB ack-UpC ou nsel
`P eterJ.W aibel(Reg.N o.43,228 )
`N O V A RTIS P H A RM A C EUTIC A L S
`C O RP O RA TIO N
`O ne H ealthP laza,B ld g.430
`EastH anover,N J07 936-108 0
`Tel.8 62-7 7 8 -7 8 38
`
`1290 A venu e ofthe A mericas
`N ew Y ork,N Y 10104-38 00
`Tel.212-218 -2100
`cjacobsen@ fchs.com
`A dditionalB ack-UpC ou nsel
`GregoryD .Ferraro (Reg.N o.36,134)
`N O V A RTIS P H A RM A C EUTIC A L S
`C O RP O RA TIO N
`O ne H ealthP laza,B ld g.430
`EastH anover,N J07 936-108 0
`Tel.8 62-7 7 8 -7 8 38
`
`A powerof attorneyfrom N ovartis d esignatingC harlotte Jacobsen,P eterJ.
`
`W aibel,and Gregory D .Ferraro is beingsu bmitted withthis N otice.
`
`S E RV IC E IN FO RM A TIO N P URS UA N T TO 37 C .F.R.§ 42.8 (b)(4)
`
`The service information has notchanged .
`
`Respectfu llysu bmitted ,
`
`D ated :O ctober4,2017
`
`/N icholas N .Kallas /
`N icholas N .Kallas
`Registration N o.31,530
`L ead C ou nselforP atentO wner
`FITZP A TRIC K,C EL L A ,H A RP ER
`& SC IN TO
`1290 A venu e ofthe A mericas
`N ew Y ork,N Y 10104-38 00
`Tel.212-218 -2100
`
`3
`
`
`
`C E RTIFIC A TE O FS E RV IC E
`
`Icertifythatacopyof P atentO wner’s Upd ated M and atoryN otices Und er
`
`37 C .F.R.§ 42.8 (a)(2)was served on O ctober4,2017 bycau singitto be sentby
`
`emailto cou nselforP etitioneratthe followingemailad d resses:
`
`D anielG.B rown (d aniel.brown@ lw.com)
`
`Jonathan M .Strang(jonathan.strang@ lw.com)
`
`B rend aL .D anek(brend a.d anek@ lw.com)
`
`Kevin L au rence (klau rence@ lpiplaw.com)
`
`M atthew P hillips (mphillips@ lpiplaw.com)
`
`TylerC .L iu (tliu @ agpharm.com)
`
`KeithA .Zu llow (kzu llow@ good winprocter.com)
`
`M artaE.D elsignore (md esignore@ good winprocter.com)
`
`D ated :O ctober4,2017
`
`/N icholas N .Kallas /
`N icholas N .Kallas
`Registration N o.31,530
`FITZP A TRIC K,C EL L A ,H A RP ER
`& SC IN TO
`1290 A venu e ofthe A mericas
`N ew Y ork,N Y 10104-38 00
`Tel.212-218 -2100
`
`4
`
`